CDMO News
uBriGene Biosciences Submits DMF for iPSC Reprogramming mRNA-LNP Kit
uBriGene Biosciences (uBriGene), cell and gene therapy CDMO has announced the submission of a Drug Master File (DMF) for its iPSC Reprogramming mRNA-LNP Kit. The regulatory filing outlines the product’s manufacturing processes, characterization, and compliance with quality standards. The iPSC Reprogramming
10 March 2025